Status of HPV vaccine introduction and barriers to country uptake. by Gallagher, KE et al.
Gallagher, KE; LaMontagne, DS; Watson-Jones, D (2018) Status of
HPV vaccine introduction and barriers to country uptake. Vaccine.
ISSN 0264-410X DOI: https://doi.org/10.1016/j.vaccine.2018.02.003
Downloaded from: http://researchonline.lshtm.ac.uk/4647187/
DOI: 10.1016/j.vaccine.2018.02.003
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Status of HPV vaccine introduction and barriers to country uptake
K.E. Gallagher a, D.S. LaMontagne b,⇑, D. Watson-Jones a,c
a London School of Hygiene & Tropical Medicine, Clinical Research Department, UK
b PATH, Centre for Vaccine Innovation & Access, Seattle, USA
cMwanza Intervention Trials Unit, Mwanza, Tanzania
a r t i c l e i n f o
Article history:
Available online xxxx
Keywords:
HPV
Vaccine
Human papillomavirus
Low income countries
Uptake
a b s t r a c t
During the last 12 years, over 80 countries have introduced national HPV vaccination programs. The
majority of these countries are high or upper-middle income countries. The barriers to HPV vaccine intro-
duction remain greatest in those countries with the highest burden of cervical cancer and the most need
for vaccination. Innovation and global leadership is required to increase and sustain introductions in low
income and lower-middle income countries.
 2018 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. The status of HPV vaccine introduction
Since first licensure of human papillomavirus (HPV) vaccines in
2006, the HPV vaccines (bivalent, quadrivalent and 9-valent) have
proven to be safe, highly immunogenic and to induce strong direct
and indirect protection against HPV and its sequelae [1–5].
National programs with just 50% coverage (or more) of 2 or 3 dose
schedules have demonstrated a dramatic impact on population
level HPV prevalence, persistent HPV infection, genital warts, and
cervical intraepithelial neoplasia [5].
By the end of 2008, a quarter of high-income and upper-middle-
income countries (HIC/UMIC) had introduced national HPV vacci-
nation programs but there had been no national introductions in
low- and lower-middle-income countries (LIC/LMIC). A recent
study estimated that by 2014, just 1.1% of girls aged 10–20 years
old in all 84 LIC/LMIC had been vaccinated with 1 or more doses
of HPV vaccine, and more than two-thirds (70%) of cervical cancer
cases occurred in countries without a national HPV vaccination
program [6]. By October 2016, 86 countries (40% of the global total
using World Bank definitions) had included HPV vaccines as a part
of their national vaccination schedule, but again introductions
were primarily in HIC/UMIC with 74 (55%) having national pro-
grams compared to only 12 LIC/LMIC (14%; Fig. 1) [7]. Worldwide,
approximately 24% of girls aged 9–14 years are were living in a
country with a national HPV program in October 2016 (World Bank
population figures).
Although the proportion of LIC/LMIC with national HPV vacci-
nation programs is still low, six new introductions took place
between 2015 [8] and 2016 [9]. This doubled the number of LIC/
LMIC with HPV vaccine programs, setting a new pace for national
introductions in the countries who need it most (Fig. 2). In addi-
tion, a further 15 LMIC and 16 LIC had delivered HPV vaccine in
at least one small scale pilot or demonstration project by May
2016 but had not yet ‘scaled-up’ to a national program (Fig. 1) [7].
Until October 2016, national introductions in low- and middle-
income countries were facilitated through pharmaceutical compa-
nies’ adhoc donations (e.g. Rwanda’s introduction in 2011/12) [9],
partner organization funding (e.g. Bhutan and Vanuatu who were
supported by the Australian Cervical Cancer Foundation [ACCF] in
2010 and 2013 respectively) [9] and the pooled procurement
mechanism of the PAHO revolving fund for governments of coun-
tries in Central and South America [7,11]. The PAHO revolving fund
has secured vaccine supply at a low price for its members (2017
list price at $8.50 per dose for bivalent and $9.80 for quadrivalent)
and therefore bridged the affordability gap for middle-income
countries who were ineligible for other vaccine funding. With this
funding support, by the end of 2016, 17 of 53 countries and terri-
tories in Central and South America had introduced the vaccine,
giving theoretical access to 87% of girls aged 9–14 years living
there [11].
More recently, LIC/LMIC were able to receive support through
Gavi, the Vaccine Alliance (e.g. Uganda in 2015). Between 2013
and 2016, Gavi provided support to over 20 eligible countries
(those with GNI per capita  $1580 US) for 2-year HPV vaccine
demonstration projects [9,12]. Gavi covered the entire cost of vac-
cines and injection consumables and partially financed delivery
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costs for two years ($4.80 US per girl or $50,000 US, whichever
amount was greater in the first year of support, and $2.40 US per
girl or $25,000 US, whichever amount was greater in the second
year of support). Countries were only eligible to apply for support
for national programs if they had experience of delivering a
multi-dose vaccine to adolescents, otherwise they could apply for
national programs in the second year of their demonstration
project funding [12]. Given Gavi’s eligibility criteria, funding for
national introduction in most LIC/LMIC only practically became
available in 2015 [10]. At the end of 2017, 47 countries remained
Fig. 1. Accumulation of global HPV vaccine experience, October 2016*7. *Reproduced with permission from the author [7]. Demonstration projects in ‘stopped’ status mainly
had fixed 1 or 2 year time periods of implementation which were not continued due to project funding ending.
* Adapted and reproduced with permission from the author [10]
Fig. 2. Percentage of countries that have included HPV vaccines as a part of their national vaccination schedule by country income group, 2000–2016, and projections for the
future* [10]. *Adapted and reproduced with permission from the author [10].
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eligible for full support from Gavi for HPV vaccine introduction,
this included all 31 LIC plus 16 LMIC (30% of 53 LMIC usingWB def-
initions). A further 11 LMIC were in the ‘accelerated transition’
phase of Gavi support and eligible for some co-financing support
for HPV vaccine costs. Although the pace of introductions in LIC/
LMIC since licensure has been slow, the pace since vaccine became
accessible to these countries, given the barriers to introduction
outlined later in this article, is encouraging [10].
Within countries, the coverage achieved by national programs
has been highly variable [8]. Among HIC, successful programs such
as those in Scotland and Australia have reached >80% of targeted
girls with the full schedule [8,13,14]. However, simultaneously,
some HIC have struggled to achieve even 50% coverage (e.g. France,
USA, Japan, Denmark) due to perceived health concerns fueled by
media coverage and/or lack of endorsement from healthcare provi-
ders [8,15,16]. Rumors about the vaccine causing disorders such as
Postural Tachycardia syndrome (POTS) or isolated episodes of mass
psychogenic illness related to receiving the vaccine have created
significant problems [16]. In the USA coverage of approximately
30% has been attributed to reliance on health facility based deliv-
ery alongside provider reluctance to recommend the vaccine
[17,18].
Although fewer LIC/LMIC than HIC/UMIC have introduced
national programs and their target population is narrower (often
restricted to 9 year-olds only or a single school grade [8] in con-
trast to the 12–26 year olds targeted in some HIC), the coverage
achieved in their national programs has been high [9]. Administra-
tive coverage estimates (number of doses delivered over the esti-
mated target population) available in mid-2016 from 4 national
programs in LIC/LMIC indicate that 80–90% of the girls targeted
received at least one dose [9] (Table 1). There have been some
rumors [19] and issues around acceptability and/or low coverage
in some LIC/LMIC but these have generally not been the reason
for the lack of national introductions in LIC/LMIC to date [9].
When estimating global HPV vaccine coverage, doses delivered
in over 66 small-scale pilots and demonstration projects in
LIC/LMIC/UMIC should be taken into account, alongside provision
through the private sector and non-government health care provi-
ders. Small scale pilots or demonstration projects were generally
funded by external donors which restricted the size and scope of
these projects to one or two districts of a country (the geographic
administrative boundary for health services), targeting between
5,000 and 25,000 girls within preset eligibility criteria (often a sin-
gle age or single grade cohort) [7,9]. Most small-scale pilots and
demonstration projects in LIC/LMIC have achieved 70–90% cover-
age with the 2 or 3 dose schedule. Data from 56 distinct delivery
strategies in 33 LIC/LMIC that implemented demonstration pro-
jects indicate median coverage with at least one dose was as high
as 93% [9]. Taking just the most recent estimates across the 34
LIC/LMIC with coverage data from national programs or demon-
stration projects up to May 2016 indicates median coverage with
at least one dose is 88% (Table 1). These coverage estimates are
supported by a small number of coverage surveys conducted after
small demonstration projects in LIC/LMIC (N = 17, median 88%;
range 72–99%) [9].
It is important to recognise that the program support from Gavi
prior to 2017 for vaccine delivery in LIC/LMIC was targeted to a sin-
gle year of age cohort from among 9–14 year olds or a single grade
[12] at school unless countries could obtain external funding or
vaccine donations from other sources. Thus, most LIC/LMICs have
had significant financial barriers to vaccinating more than a single
year of age cohort each year. Although coverage has generally been
high in these specific target populations, the numbers vaccinated
as a proportion of the total female population above the age of 9
years may always be lower than in HIC where delivery has often
been given to an wider age range through catch-up campaigns that
may include vaccinating girls aged up to 26 years (e.g. Australia)
[13].
Since the end of 2014, when an estimated 1.2% of 10–14 year-
olds in LIC/LMIC had received at least one dose of the vaccine, a
large number of girls have been vaccinated [6]. The aforemen-
tioned 66 demonstration projects and pilots run by key stakehold-
ers have demonstrated political will and a recognition of the need
to introduce the vaccine for cervical cancer prevention. Addition-
ally, some countries have implemented a third ‘bridging year’ of
HPV vaccine delivery to their demonstration project district while
the country gains approval for its national HPV program. Changes
in Gavi policy to provide HPV vaccine support for national pro-
grams, without requiring a demonstration project first, and to deli-
ver to a multi-year cohort of 9–14 year-old girls in the first year of
national introduction will enable an acceleration of national pro-
grams in LIC/LMIC from 2017 onwards. A further 11 LIC/LMIC have
been approved for national programs, scheduled to launch in 2018
and 2019. All but one of these programs are targeting girls aged 9–
14 years during the first year of national scale-up and then rou-
tinely vaccinating all new cohorts of 9 year old girls in the subse-
quent years. Projections by Gavi and other partners indicate a
further 15 countries will apply for support for national introduc-
tions of HPV vaccine over the next few years (Fig. 2).
2. The importance of HPV vaccine introduction in LIC/LMIC
It will be important to continue to expand vaccination availabil-
ity since the other main intervention to prevent cervical cancer,
cervical screening, remains challenging to implement in many
LIC/LMIC where more than 85% of cervical cancer cases occur.
The impact that cytology-based screening has had on cervical can-
cer rates in HIC has not been replicable in low-resource settings
[20]. Cytology-based screening methods require substantial logis-
tical and human resources and necessitate women to return at reg-
ular intervals for re-screening due to the low sensitivity of
cytological screening [20].
Although globally, 25 countries have introduced national VIA-
based screening programs, among LIC/LMICs services are generally
Table 1
Coverage of at least one dose in 34 distinct LIC/LMIC (taking the most recent data available by May 2016 [9].
Countries classified by Income group and
most recent program/project
Number of countries with data Coverage with at least 1 dose of HPV vaccine
90% 80–89% 70–79% 60–69% Median
National program
LIC 1 1 (100%) NA
LMIC 3 1 (33%) 1 (33%) 1 (33%) 84%
Demonstration project
LIC 14 7 (50%) 4 (29%) 2 (14%) 1 (7%) 89.5%
LMIC 16 7 (44%) 5 (31%) 4 (25%) 88%
Total 34 16 (47%) 10 (29%) 7 (21%) 1 (3%) 88.5%
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restricted to small scale pilots [21] or heterogeneous coverage via
ad-hoc service provision from non-governmental organizations.
Even in countries with national programs, coverage is often low,
at around 10–20% of adult women in the poorest countries [22].
HPV testing using self-collected samples has the potential to
increase coverage of screening services significantly, especially in
hard to reach populations [22]. In Uganda, HPV testing using
self-collected samples achieved 95% uptake, compared with 48%
coverage using VIA [22]. However, until low-cost point of care tests
become widely available, HPV testing remains expensive to estab-
lish and maintain as a primary screening test. Additionally, the
specificity of HPV testing may favor treatment algorithms that
include a second diagnostic test but this is not ideal in countries
where currently the only chance of achieving good coverage is with
a single visit algorithm [20]. The most cost-effective methods to
triage and treat HPV-infected women in LIC/LMIC are yet to be
determined [22,23]. HPV testing as a screening method has only
been in the form of small scale demonstration projects to date,
with no known national introductions in LIC/LMIC [20].
Despite innovations in screening and self-collection of samples,
the estimated percentage of women who are accessed by at least
one screening test in their lifetime and treated for precancers is
still very low in LIC/LMIC [22]. More than 85% of all cervical cancer
cancers and deaths are in LIC/LMICs (Table 2). The increased bur-
den of cervical cancer among HIV-infected women increases the
potential impact of vaccination in some LIC/LMIC. However, given
the target age group for vaccination, 9–13 year-old girls in most
LIC/LMIC, it is projected to take decades for the current coverage
of vaccination and screening services to impact cervical cancer
rates [24].
3. Challenges in implementing HPV vaccination programs in
LIC/LMIC
There are multiple factors affecting HPV vaccine introduction in
LIC/LMIC; historical, programmatic, and residual barriers to HPV
vaccine introduction are highlighted below.
3.1. Historical/structural
Despite vaccine licensure in 2006 and rapid uptake by some
HIC, funding and support for introductions in LIC/LMIC only
became available to the poorest countries in 2013 through Gavi
and even then it was in practice restricted to demonstration pro-
jects until countries accrued some experience in delivering a new
vaccine to young adolescents. For most countries, this meant that
funding for national introductions was available from 2015, after
the first two-year demonstration projects were completed. Prior
to price negotiations through Gavi, the vaccine was prohibitively
expensive for LIC at >$100 US per dose. Gavi negotiated supply at
$4.50–4.60 US per dose. The only national programs in LIC before
2015 were through donations from pharmaceutical companies or
NGO support (e.g. Rwanda, Lesotho, Bhutan, Vanuatu). In this con-
text, the 12 national introductions among LIC/LMIC within two
years from funding and affordable vaccine really being available
(2015–2016) are encouraging [10].
3.2. Programmatic
Gavi supported HPV vaccine delivery in over 20 demonstration
projects between 2013 and 2016. By the July 2017, nine of these
countries had made national decisions to scale up and received
approval from Gavi for vaccine support and financing. A further
two had approval to conduct Gavi national programs without con-
ducting a demonstration project. However, for many LMICs, there
are still significant programmatic and financial barriers to imple-
menting HPV vaccine nationally. Pneumococcal conjugate vaccine
(PCV), rotavirus and inactivated polio vaccines, which are more
easily integrated into the existing infant EPI schedule than HPV
vaccine and are accompanied by influential access models, e.g.
the Accelerated Development and Introduction Plans (ADIPs) [10]
and The Polio Endgame [26]2, may compete with HPV vaccine for
the limited financial and human resources required for new vac-
cine introduction [27,28].
Despite co-financing of vaccine supply for Gavi eligible coun-
tries, co-financing commitments have been unaffordable for some
countries with large populations and multiple new vaccine intro-
ductions in the past year, e.g. PCV and rotavirus vaccines [29].
Competing priorities have led to some of the earlier introductions
of infant vaccines to be continued (for now) at the expense of plans
to scale-up HPV vaccination. Countries approaching the threshold
Gavi eligibility threshold (GNI per capita rises >$1580 US) must
plan to enter a 5-year transition phase with a year-to-year increase
of co-financing commitments each year, until the country is fully
financing their EPI program. During the period 2014–2016 some
Gavi countries only funded 15–30% of their routine immunization
programs [29]. Even the cost of a two-dose schedule to girls is seen
as too expensive at the current Gavi vaccine price of $4.50 US per
dose. Imminent ‘transition’ out of Gavi support understandably has
led to reluctance among policy makers and ministries of finance to
commit to another new vaccine introduction.
There is evidence from a number of demonstration projects and
studies, e.g. Vietnam, Uganda, and Rwanda, that vaccine delivery
does not have to be expensive [30,31]. If supported by Gavi for
demonstration projects, countries received substantial funds to
cover the delivery cost of the vaccine. Most countries used these
funds to conduct a specific HPV vaccination campaign with little
integration into existing services or routine immunization pro-
grams since the demonstration project was usually implemented
in a small area of the country. The older age of the target group also
made integration into the routine immunization system more
challenging than for infant vaccinations. Generally, the demonstra-
tion projects used all of the available funds from Gavi and therefore
cost analyses indicated a high cost of delivery per dose. The mean
cost of delivery in a five country analyses was $6.00 US per dose for
a campaign style delivery including mobilization, training, delivery
and some evaluation [9]. The largest proportions of delivery costs
were allocated to transportation and per diem costs for health
Table 2
the proportion of countries with national HPV vaccination programs and their cervical cancer burden.
Income group Number of national HPV
vaccine programs
Number of cervical cancer cases
in women estimated 2012a
Cervical cancer incidence rate/100,000
women yearsb
Cervical Cancer mortality rate/100,000
women yearsb
HIC/UMIC 74/134 (55%) 83,078 (14%) 9.9 3.3
LIC/LMIC 12/84 (14%) 444,546 (86%) 15.7 8.3
a Data in HIC/UMIC are strongly influenced by the large population of China (UMIC) with an estimated 61,691 active cases in 2012, incidence rate of 7.5/100,000 and a
mortality rate of 3.4/100,000. Data in LIC/LMIC are heavily influenced by the large population of India (LMIC), with an estimated 122,824 cases of cervical cancer in 2012, an
incidence rate of 22.0 and a mortality rate of 12.4/100,000 women.
b Age-standardized rates from 2012 [25].
4 K.E. Gallagher et al. / Vaccine xxx (2018) xxx–xxx
Please cite this article in press as: Gallagher KE et al. Status of HPV vaccine introduction and barriers to country uptake. Vaccine (2018), https://doi.org/
10.1016/j.vaccine.2018.02.003
workers and supervisors to travel to schools but social mobiliza-
tion activities also accounted for a large proportion of funds in cost
analyses [32]. Policy makers perceived that delivery of HPV vaccine
was expensive and unsustainable. For national vaccination pro-
grams, including HPV vaccine programs, Gavi does not provide
support for delivery costs and this was a factor contributing to a
number of LIC deciding not to scale-up immediately after their
demonstration projects [9,27].
At the end of 2017 it remained unclear as to whether the 26
(49%) LMIC not eligible for full or partial support from Gavi would
introduce HPV vaccination (21 countries) or sustain their programs
(5 countries). These countries constitute the ‘missing middle’,
unable to afford the vaccine at negotiated prices with the manufac-
turers but equally ineligible for donor support. India is an impor-
tant country among the 21 LMIC yet to introduce and ineligible
for full Gavi support. The number of 9–14 year old girls living in
a country with a national program would increase by approxi-
mately 71.9 million if introduction occurred nationally across India
and bring the proportion of 9–14 year old girls living in a country
with a national program to approximately 44%.
3.3. Residual barriers to delivery now
In countries that have not yet introduced HPV vaccine, new Gavi
guidelines indicate that countries applying for HPV vaccine sup-
port in 2017 onwards should do so for a national program. Funding
will be supplied through a vaccine introduction grant (VIG) of
$2.40 US per girl in a single age cohort, e.g. girls aged 9 years, to
support the startup of the national program in the first year, e.g.
training and social mobilization, as per Gavi policy for other vac-
cine introductions. Additionally in the first year, a multi-age cohort
can be targeted and vaccine will be supplied at no cost for the esti-
mated target population between 10 and 14 years of age for the
first year only. Operational support for the costs of delivery to
the additional multi-age cohort of girls will be commensurate with
the amount given for other campaigns at $0.65 US per eligible girl
[33]. For countries with no HPV vaccine experience but confidence
that they can deliver a national program, this is likely to reduce the
barriers to introduce and increase coverage in LIC/LMIC. However,
issues of competing priorities are likely to remain, as well as the
reluctance to commit to another new vaccine introduction if grad-
uation from Gavi support is imminent. The required political will
and commitment to take on a national program is greater than that
needed to apply for a demonstration project that was almost fully
funded by Gavi.
In-school delivery strategies with some strategy to reach out of
schoolgirls are to date the predominant delivery strategy chosen to
achieve high coverage and delivery is still perceived as expensive,
although there have been experiences that have proved the con-
trary [34,35]. The HPV demonstration program in Bangladesh doc-
umented 87% coverage with school-based delivery at a financial
cost of delivery per dose of just $0.57 US (vaccine provided by Gavi
at no cost), which was achieved by including HPV vaccine delivery
into health worker’s expected job duties with no additional com-
pensation [36,37], [pers. Communication D.S. LaMontagne]. Experi-
ence with routine, non-campaign style delivery on a national scale
is limited and needs to be expanded to assess the achievable cov-
erage and the cost of such using this strategy in different settings.
Vaccine delivery is not necessarily expensive when integrated
more fully into the regular EPI program structure and processes
and high coverage can be achieved [38,39].
Supply of HPV vaccines needs to be maintained and needs to
have the capacity to increase as and when demand increases
globally. Limited competition in the current market may be
keeping vaccine procurement prices high. It is unclear how the
new nonavalent vaccine will be priced or whether it would be pro-
cured by either Gavi or the PAHO revolving fund.
Acceptability among the community and prompt address of
rumors needs to be maintained as these can derail vaccine pro-
grams. Given the experiences in Japan [16], India [40], and Den-
mark [41], the global community needs to remain vigilant and
share lessons to prevent rumors or episodes of psychogenic illness
affecting delivery in LIC/LMIC.
The focus on attaining 100% coverage can be unhelpful. Signifi-
cant impact of vaccination on disease could be achieved with cov-
erage even lower than 40% [5,24,42]. Introduction should be
encouraged, alongside experimentation with delivery strategies
and intervals between doses to enable countries to design their
own sustainable programs, even if this means a few years of lower
coverage than could be achieved with a campaign. Although drop-
out rates in small scale demonstration projects and national pro-
grams in LIC/LMIC to date have been very low, with the majority
achieving 10% dropout [9], the ability to track girls and maintain
adherence in multi-year cohorts targeting 9–14 year-old girls
needs to be monitored.
4. Catalysing national scale up in LIC/LMICs
The change in Gavi guidelines for support of HPV vaccination
programs may mean broader target populations in first year and
more national introductions. Forward projections indicate that by
2020, 48% of LIC/LMIC may have introduced the vaccine [10].
New programs could be designed more efficiently, which may
encourage some of the countries that have become hesitant since
their demonstration projects to introduce HPV vaccines immi-
nently. Larger multi-year cohorts could be vaccinated with less fre-
quent campaigns. For example, the current two-dose schedule
could be delivered as one dose every 12 months rather than every
6 months.
There is some evidence that one dose of HPV vaccine may be
enough to stimulate a protective immune response [4,43]; how-
ever, the duration of vaccine-induced protection and the applicabil-
ity of reduced schedules for HIV-positive girls remain unclear.
Randomised controlled trials to assess immunogenicity and efficacy
of a one-dose regimen are ongoing [44,45]; if successful, HPV vac-
cine schedules may reduce even further. A one-dose regimen may
help to overcome a number of the barriers to national introduction
described previously and accelerate the currently projected fast
pace of national introductions in LIC/LMIC in the next few years:
– Vaccine supply costs would halve if a one-dose schedule proves
effective. At $4.50 US per dose, HPV vaccine would remain an
expensive per unit cost in comparison with other vaccines;
however, delivery to girls only would keep the cost of the pro-
gram lower than other multi-dose regimens to entire birth
cohorts (for female and male infants), e.g. three-dose pneumo-
coccal conjugate vaccination programs.
– The schedule may be logistically easier to deliver and easier to
integrate into routine delivery by specifying delivery on a cer-
tain birthday or when a child reaches a certain grade in school
or be easier to combine with annual vaccination events such as
national immunization weeks, tetanus toxoid campaigns, or
annual school health days. One-dose may allow wider age
cohorts to be vaccinated within the same funding envelope
for delivery, especially if vaccine is delivered to all ages in a
mass national campaign like activities implemented during
the Africa Vaccination Week [46].
– Recurrent costs related to delivery of the vaccine may fall,
although many start-up costs, e.g., training, microplanning,
social mobilization, will remain.
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– The perceived challenges of delivering a multi-dose schedule to
adolescents and concerns over the capacity of the workforce to
achieve good coverage in this target population may decrease,
making HPV vaccine seem more like a relatively ‘easy win’.
– Perceived delivery costs (both opportunity costs and financial
costs) among policy-makers may fall and this may aid policy
makers to prioritise the vaccine over other expenditures in
the health program.
– Metrics of the success of the program, e.g. coverage, would be
easier to track with the use of a simple register or card and no
loss-to-follow-up.
– A one-dose regimen may extend existing vaccine supply for a
longer period and/or for more individuals.
– Countries with sufficient funds and supply may be able to
decide whether to vaccinate a broader age cohort of young
women or extend vaccination to cohorts of young men also.
5. Conclusion
Substantial progress has been made; over 80 countries world-
wide now have HPV vaccination programs; the barriers to HPV
vaccine introduction remain greatest in those countries with the
highest burden of cervical cancer and the most need for vaccina-
tion. Funding for eligible LIC/LMIC is available through Gavi to
vaccinate 40 million girls by 2020; however, international commit-
ment is needed to maintain current HPV vaccine programs and
extend support after 2020. In the long-term, work is needed to
ensure a sustainable structure of international funding and support
and to strengthen health systems and immunization programs in
order for HPV vaccine to become just one of a platform of services
delivered to young men and women. In the short-term, if one-dose
HPV vaccination became viable, some of the significant barriers to
scale-up and sustained use in LIC/LMIC may be overcome.
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